ELXR

Welcome to the Brand page for “ELXR”, which is offered here for Pharmaceutical and biological preparations based on genetic engineering and gene therapy for use in diagnosis, prevention, and treatment of diseases in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; gene therapy products, biological preparations based on engineered cells for medical use for the treatment of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder related to immuno-oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology; pharmaceutical and biological preparations based on gene, genome, and cellular editing, modulation, and modification for use in human therapeutics in the nature of diseases caused by genetic mutations or for which gene modification would ameliorate or cure the disease or disorder; pharmaceutical preparations, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders, neurological disorders, huntington's disease, amyotrophic lateral sclerosis (als), front temporal dementia, pain, alzheimer's, parkinson's, ataxia, autism, epilepsy, pain, and also cardiovascular, peripheral nervous system, cancer, endocrine, gastrointestinal, renal, genetic immunological, hepatic, infectious, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, respiratory, urogenital, urological, hematologic and viral or bacterial diseases and disorders;.

Its status is currently believed to be active. Its class is unavailable. “ELXR” is believed to be currently owned by “Scribe Therapeutics Inc.”